NewsAI-assisted
NeuroBo Transforms into MetaVia Inc.
NeuroBo becomes MetaVia, focusing on MASH and obesity therapies with key trials nearing milestone results.
By Mrudula Kulkarni
Managing Editor - Pharma Now
Nov 19, 2024Updated Jun 26, 2025 · 2 min read
AI-assisted reporting
Reviewed by Mrudula Kulkarni, Managing Editor - Pharma Now
NeuroBo Pharmaceuticals, soon to be renamed MetaVia Inc., is realigning its corporate identity to focus on cardiometabolic disease therapies, with the transition effective November 29, 2024. Trading on Nasdaq under the new ticker MTVA, MetaVia aims to highlight its innovative pipeline, including:
- DA-1241: A GPR119 agonist for metabolic dysfunction-associated steatohepatitis (MASH), with Phase 2a trial data expected in December 2024.
- DA-1726: A dual OXM analog for obesity, with top-line Phase 1 MAD cohort results anticipated in Q1 2025.
MetaVia emphasizes its strong funding foundation and ambition to deliver next-generation treatments.
TopicsNews
Written by
Mrudula Kulkarni
Managing Editor - Pharma Now
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
News
IDEAYA Biosciences Achieves 17.4-Month Median OS with IDE849 ADC in Relapsed SCLC
Vaibhavi M. · Oct 23, 2026
News
FDA Issues Twelve Biologics Guidance Documents Covering Container Closure, Blood Manufacturing, and Biosimilars
Vaibhavi M. · Oct 23, 2026
News
AMA and EMA Issue Joint Guidance on Bundibugyo Ebola Vaccine Clinical Trial Requirements
Vaibhavi M. · Oct 23, 2026
Discussion